Quantcast
Last updated on April 24, 2014 at 5:50 EDT

Latest TYSABRI Stories

2013-12-12 12:26:15

Recent Changes Include Earlier and More-Aggressive Treatment, According to a New Report from BioTrends Research Group EXTON, Pa., Dec. 12, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that physician-reported patient shares for Novartis's Gilenya and Biogen Idec's Tysabri are 8 percent and 10 percent among relapsing-remitting multiple sclerosis (RR-MS) patients treated with a...

2013-10-01 08:31:54

NEW YORK, Oct. 1, 2013 /PRNewswire-USNewswire/ -- The National Multiple Sclerosis Society today announced that it has entered into a research collaboration agreement with GE Healthcare through Fast Forward, a not for profit subsidiary of the National Multiple Sclerosis Society, to co-fund a clinical study with the GE investigational PET tracer, GE180, in patients with multiple sclerosis (MS). The clinical study, which will be enrolling patients in the United Kingdom, is aimed to aid...

2013-09-24 23:19:33

Reportbuyer.com just published a new market research report: Inflammatory Bowel Diseases: World Drug Market 2013-2023. London (PRWEB) September 24, 2013 Report Details Medicines for bowel inflammation - you explore R&D and potential sales What's the future for treating inflammatory bowel diseases (IBD)? Visiongain's updated report gives you revenue predictions from 2013, helping you stay ahead. There you find financial results, R&D trends, opportunities, and potential...

2013-06-11 12:29:04

IF ELAN STOCKHOLDERS APPROVE ANY OF THE FOUR PROPOSED TRANSACTIONS, ROYALTY PHARMA WILL BE REQUIRED TO LAPSE ITS OFFER(I),(II) NEW YORK, June 11, 2013 /PRNewswire/ -- Royalty Pharma today announced that it believes Elan's (NYSE: ELN) disclosure in its May 27( )EGM Circular is misleading and inadequate, in Royalty Pharma's view, because it fails to: Regarding the entire package of proposed transactions: disclose that the Theravance, AOP, Speranza and inconsequential...

2013-06-10 08:29:10

ADS Shareholders Have Only Three Days to Vote NEW YORK, June 10, 2013 /PRNewswire/ -- Royalty Pharma today urged Elan Corporation, plc (NYSE: ELN) Shareholders to immediately vote AGAINST ALL FOUR resolutions Elan's Board has put forth for the Extraordinary General Meeting ("Elan EGM") on June 17. To meet the official voting deadlines: Holders of Elan American Depository Receipts held in street name may only vote their proxies through BroadRidge up to 11:59 PM New York time...

2013-03-06 08:26:20

This announcement does not constitute an announcement of a firm intention to make an offer under the Irish Takeover Rules NEW YORK, March 6, 2013 /PRNewswire/ -- RP Management, LLC ("Royalty Pharma") remains committed to acquiring Elan (NYSE: ELN) on the terms set out in the Proposal Announcement of February 25, 2013, but continues to be disappointed that the Board of Elan has not engaged in discussions. Royalty Pharma is ready and able to move quickly to implement an offer and...

2012-06-13 10:24:22

INCLINE VILLAGE, Nev., June 13, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the second quarter ending June 30, 2012, of approximately $125 million, as compared with actual royalty revenue of $122 million for the second quarter of 2011, a two percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) The forecasted growth in royalty revenues is driven by increased first quarter 2012 sales of...

2012-05-23 02:26:59

TORONTO, May 23, 2012 /CNW/ - Today Biogen Idec announced that Health Canada has approved a product monograph change for TYSABRI® that will help enable individual benefit risk assessment for patients with multiple sclerosis (MS). The new label identifies anti-JC virus (JCV) antibody status as a risk factor for developing an uncommon, but serious, brain infection known as progressive multifocal leukoencephalopathy (PML). This marks the third risk factor identified to help...

2012-01-20 15:00:00

MADISON, N.J., Jan. 20, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted a de novo classification petition to its STRATIFY JCV(TM) Antibody ELISA testing service. STRATIFY JCV is the first blood test to be FDA market authorized for the qualitative detection of antibodies to the polyomavirus JC virus (JCV) for stratifying risk for...

2012-01-20 14:45:00

SILVER SPRING, Md., Jan. 20, 2012 /PRNewswire-USNewswire/ -- Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn's disease (CD). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) The Stratify JCV Antibody ELISA test, when used with other clinical data...